{"id":"https://openalex.org/W2007644267","doi":"https://doi.org/10.1182/blood-2009-03-213009","title":"Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma","display_name":"Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma","publication_year":2009,"publication_date":"2009-11-14","ids":{"openalex":"https://openalex.org/W2007644267","doi":"https://doi.org/10.1182/blood-2009-03-213009","mag":"2007644267","pmid":"https://pubmed.ncbi.nlm.nih.gov/19965674","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2815518"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2009-03-213009","doi":"https://doi.org/10.1182/blood-2009-03-213009","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2009-03-213009","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2815518","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006765393","display_name":"Dharminder Chauhan","orcid":"https://orcid.org/0000-0002-5548-6138","observed_orcids":["https://orcid.org/0000-0002-5548-6138"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dharminder Chauhan","raw_affiliation_strings":["LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102256659","display_name":"Ajita Singh","orcid":"https://orcid.org/0000-0002-6070-4232","observed_orcids":["https://orcid.org/0000-0002-6070-4232"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ajita V. Singh","raw_affiliation_strings":["LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047642604","display_name":"Bryan T. Ciccarelli","orcid":"https://orcid.org/0000-0002-7461-8925","observed_orcids":["https://orcid.org/0000-0002-7461-8925"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan Ciccarelli","raw_affiliation_strings":["LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul G. Richardson","raw_affiliation_strings":["LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000260833","display_name":"Michael A. Palladino","orcid":"https://orcid.org/0000-0002-4687-7612","observed_orcids":["https://orcid.org/0000-0002-4687-7612"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael A. Palladino","raw_affiliation_strings":["Nereus Pharmaceuticals, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nereus Pharmaceuticals, San Diego, CA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5006765393","https://openalex.org/A5102256659"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":8.6319,"has_fulltext":false,"cited_by_count":108,"citation_normalized_percentile":{"value":0.97968885,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"115","issue":"4","first_page":"834","last_page":"845"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.006399999838322401,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/npi-0052","display_name":"NPI-0052","score":0.9959999918937683},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9700000286102295},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9860000014305115},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9039999842643738},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7710000276565552},{"id":"https://openalex.org/keywords/synergistic-cytotoxicity","display_name":"synergistic cytotoxicity","score":0.9290000200271606},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.9810000061988831},{"id":"https://openalex.org/keywords/caspase-8","display_name":"caspase-8","score":0.9570000171661377},{"id":"https://openalex.org/keywords/caspase-9","display_name":"caspase-9","score":0.890999972820282},{"id":"https://openalex.org/keywords/building-information-modeling","display_name":"building information modeling","score":0.9359999895095825},{"id":"https://openalex.org/keywords/endoplasmic-reticulum-translocation","display_name":"endoplasmic reticulum translocation","score":0.9139999747276306},{"id":"https://openalex.org/keywords/bortezomib-resistance","display_name":"bortezomib resistance","score":0.8759999871253967},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.7179999947547913},{"id":"https://openalex.org/keywords/tumor-cell-migration","display_name":"tumor cell migration","score":0.675000011920929},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.9034532904624939},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7571725845336914},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6334598660469055},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.6257360577583313},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6038038730621338},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5440797209739685},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.5437851548194885},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46923643350601196},{"id":"https://openalex.org/C12519072","wikidata":"https://www.wikidata.org/wiki/Q14914370","display_name":"Caspase 3","level":4,"score":0.4550446569919586},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.41965609788894653},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3834381401538849},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3606269359588623},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20148435235023499},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1856670081615448},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.1481577455997467},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08417707681655884},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002455","descriptor_name":"Cell Division","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002470","descriptor_name":"Cell Survival","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007783","descriptor_name":"Lactones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D016513","descriptor_name":"Mice, SCID","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061988","descriptor_name":"Proteasome Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066298","descriptor_name":"In Vitro Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1182/blood-2009-03-213009","doi":"https://doi.org/10.1182/blood-2009-03-213009","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2009-03-213009","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2025122","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2815518","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:2815518","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2815518","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"Text"},{"id":"pmid:19965674","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19965674","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"Journal Article"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:2025122","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2815518","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3006657251","display_name":null,"funder_award_id":"P50100707","funder_id":"https://openalex.org/F4320332505","funder_display_name":"U.S. Public Health Service"},{"id":"https://openalex.org/G3549977710","display_name":"Host-tumor cell interaction in myeloma: therapeutic applications","funder_award_id":"5p01ca078378-15","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G4680808690","display_name":null,"funder_award_id":"P01-CA078378","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G4933731489","display_name":"SPORE in Multiple Myeloma","funder_award_id":"P50CA100707","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G5276536440","display_name":"Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications","funder_award_id":"R01CA050947","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000867162","display_name":"Integrative Oncogenomics of Multiple Myeloma","funder_award_id":"P01CA155258","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332505","display_name":"U.S. Public Health Service","ror":"https://ror.org/05xf94514"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":48,"referenced_works":["https://openalex.org/W150727265","https://openalex.org/W1520422891","https://openalex.org/W1969894269","https://openalex.org/W1980471295","https://openalex.org/W1984611855","https://openalex.org/W1987583882","https://openalex.org/W1995246165","https://openalex.org/W1996180957","https://openalex.org/W2010184965","https://openalex.org/W2010298858","https://openalex.org/W2010552629","https://openalex.org/W2024076223","https://openalex.org/W2026642838","https://openalex.org/W2030902700","https://openalex.org/W2034213169","https://openalex.org/W2041448202","https://openalex.org/W2059398696","https://openalex.org/W2059873406","https://openalex.org/W2064137692","https://openalex.org/W2064950130","https://openalex.org/W2067653691","https://openalex.org/W2076710136","https://openalex.org/W2077945404","https://openalex.org/W2087843841","https://openalex.org/W2091823485","https://openalex.org/W2096207943","https://openalex.org/W2097290512","https://openalex.org/W2103209498","https://openalex.org/W2104148554","https://openalex.org/W2106906885","https://openalex.org/W2108235071","https://openalex.org/W2118820477","https://openalex.org/W2119810076","https://openalex.org/W2124560610","https://openalex.org/W2132485651","https://openalex.org/W2133986577","https://openalex.org/W2142149038","https://openalex.org/W2145412346","https://openalex.org/W2148537814","https://openalex.org/W2152065071","https://openalex.org/W2154374454","https://openalex.org/W2159679541","https://openalex.org/W2163679078","https://openalex.org/W2171194005","https://openalex.org/W2171513236","https://openalex.org/W2555603866","https://openalex.org/W2564026069","https://openalex.org/W6681914775"],"related_works":["https://openalex.org/W2560359838","https://openalex.org/W1968882794","https://openalex.org/W2010184965","https://openalex.org/W7096145386","https://openalex.org/W1987583882","https://openalex.org/W2400993640","https://openalex.org/W2910942915","https://openalex.org/W2588338482","https://openalex.org/W2243792761","https://openalex.org/W2612365855"],"abstract_inverted_index":{"Our":[0],"recent":[1],"study":[2,156],"demonstrated":[3],"that":[4,30,121],"a":[5],"novel":[6],"proteasome":[7,97],"inhibitor":[8],"NPI-0052":[9,32,49,107,122,140,168],"is":[10,53,126,143],"distinct":[11],"from":[12],"bortezomib":[13],"(Velcade)":[14],"and,":[15],"importantly,":[16],"triggers":[17],"apoptosis":[18,52,125],"in":[19,40,173],"multiple":[20],"myeloma":[21],"(MM)":[22],"cells":[23,86],"resistant":[24],"to":[25,77,169],"bortezomib.":[26],"Here":[27],"we":[28],"demonstrate":[29,120],"combining":[31],"and":[33,63,87,89,95,141,150],"lenalidomide":[34,142,165],"(Revlimid)":[35],"induces":[36],"synergistic":[37],"anti-MM":[38],"activity":[39],"vitro":[41],"using":[42,103,113],"MM-cell":[43],"lines":[44],"or":[45],"patient":[46,171],"MM":[47,85],"cells.":[48],"plus":[50,108,123],"lenalidomide-induced":[51,109],"associated":[54],"with":[55,167],"(1)":[56],"activation":[57,68],"of":[58,69,75,82,84,92,101,116,139],"caspase-8,":[59],"caspase-9,":[60],"caspase-12,":[61],"caspase-3,":[62],"poly(ADP)":[64],"ribose":[65],"polymerase;":[66],"(2)":[67],"BH-3":[70],"protein":[71],"BIM;":[72],"(3)":[73],"translocation":[74],"BIM":[76,102],"endoplasmic":[78],"reticulum;":[79],"(4)":[80],"inhibition":[81],"migration":[83],"angiogenesis;":[88],"(5)":[90],"suppression":[91],"chymotrypsin-like,":[93],"caspase-like,":[94],"trypsin-like":[96],"activities.":[98],"Importantly,":[99],"blockade":[100],"siRNA":[104],"significantly":[105,146],"abrogates":[106],"apoptosis.":[110],"Furthermore,":[111],"studies":[112],"biochemical":[114],"inhibitors":[115],"caspase-8":[117,130],"versus":[118],"caspase-9":[119],"lenalidomide-triggered":[124],"primarily":[127],"dependent":[128],"on":[129],"signaling.":[131],"In":[132],"animal":[133],"tumor":[134,148],"model":[135],"studies,":[136],"low-dose":[137],"combination":[138],"well":[144],"tolerated,":[145],"inhibits":[147],"growth,":[149],"prolongs":[151],"survival.":[152],"Taken":[153],"together,":[154],"our":[155],"provides":[157],"the":[158],"preclinical":[159],"rationale":[160],"for":[161],"clinical":[162],"protocols":[163],"evaluating":[164],"together":[166],"improve":[170],"outcome":[172],"MM.":[174]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":15},{"year":2012,"cited_by_count":17}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}